Vanoxerine free base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 504510

CAS#: 67469-69-9 (free base)

Description: Vanoxerine, also known as GBR-12909; I-893, is a dopamine ruptake inhibitor potentially for the treatment of atrial fibrillation.

Chemical Structure

Vanoxerine free base
CAS# 67469-69-9 (free base)

Theoretical Analysis

MedKoo Cat#: 504510
Name: Vanoxerine free base
CAS#: 67469-69-9 (free base)
Chemical Formula: C28H32F2N2O
Exact Mass: 450.24827
Molecular Weight: 450.56
Elemental Analysis: C, 74.64; H, 7.16; F, 8.43; N, 6.22; O, 3.55

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2021-03-08. Prices are subject to change without notice.

Vanoxerine free base is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Related CAS #: 67469-69-9 (free base)   67469-78-7 (HCl)    

Synonym: Vanoxerine; GBR-12909; GBR12909; GBR 12909; I-893; I 893; I893.

IUPAC/Chemical Name: 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine


InChi Code: InChI=1S/C28H32F2N2O/c29-26-12-8-24(9-13-26)28(25-10-14-27(30)15-11-25)33-22-21-32-19-17-31(18-20-32)16-4-7-23-5-2-1-3-6-23/h1-3,5-6,8-15,28H,4,7,16-22H2


Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>5 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Handling Instructions:

Preparing Stock Solutions

The following data is based on the product molecular weight 450.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Cakulev I, Lacerda AE, Khrestian CM, Ryu K, Brown AM, Waldo AL. Oral vanoxerine prevents reinduction of atrial tachyarrhythmias: preliminary results. J Cardiovasc Electrophysiol. 2011 Nov;22(11):1266-73. doi: 10.1111/j.1540-8167.2011.02098.x. Epub 2011 May 26. PubMed PMID: 21615815; PubMed Central PMCID: PMC3172341.

2: Matsumoto N, Khrestian CM, Ryu K, Lacerda AE, Brown AM, Waldo AL. Vanoxerine, a new drug for terminating atrial fibrillation and flutter. J Cardiovasc Electrophysiol. 2010 Mar;21(3):311-9. Epub 2009 Oct 8. PubMed PMID: 19817929.

3: Lacerda AE, Kuryshev YA, Yan GX, Waldo AL, Brown AM. Vanoxerine: cellular mechanism of a new antiarrhythmic. J Cardiovasc Electrophysiol. 2010 Mar;21(3):301-10. Epub 2009 Oct 8. PubMed PMID: 19817928; PubMed Central PMCID: PMC3107714.

4: Cherstniakova SA, Bi D, Fuller DR, Mojsiak JZ, Collins JM, Cantilena LR. Metabolism of vanoxerine, 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine, by human cytochrome P450 enzymes. Drug Metab Dispos. 2001 Sep;29(9):1216-20. PubMed PMID: 11502731.

5: Preti A. Vanoxerine National Institute on Drug Abuse. Curr Opin Investig Drugs. 2000 Oct;1(2):241-51. PubMed PMID: 11249581.

6: Ingwersen SH, Snel S, Mant TG, Edwards D. Nonlinear multiple-dose pharmacokinetics of the dopamine reuptake inhibitor vanoxerine. J Pharm Sci. 1993 Nov;82(11):1164-6. PubMed PMID: 8289134.

7: Ingwersen SH, Mant TG, Larsen JJ. Food intake increases the relative oral bioavailability of vanoxerine. Br J Clin Pharmacol. 1993 Mar;35(3):308-10. PubMed PMID: 8471409; PubMed Central PMCID: PMC1381581.

8: Ingwersen SH. Column liquid chromatographic assay of the dopamine reuptake inhibitor vanoxerine (GBR 12909) in human serum. J Chromatogr. 1991 Nov 15;571(1-2):305-11. PubMed PMID: 1839795.

Additional Information

Related CAS#
67469-69-6 (Vanoxerine)
67469-78-7 (Vanoxerine Hydrochloride)